GSK Entered into an Exclusive License Agreement with Spero Therapeutics for Tebipenem HBr to Treat Urinary Tract Infections
- Spero to receive $66M up front, ~$150M in development, ~$150M in a commercial on first sale (US/EU) & ~$225M in sales milestones along with royalties, if sales exceed $1B, $9M in shares of Spero common stock. The transactions are expected to close in Q4’22
- GSK to get an exclusive license to develop & commercialize tebipenem pivoxil & tebipenem pivoxil HBr in all territories (Ex- Japan & other Asian countries). Spero will lead the execution & costs of the follow-up P-III trial of tebipenem HBr while GSK will responsible for additional development, incl. P-III regulatory filing & commercialization activities for tebipenem HBr outside of the Meiji Seika territory
- The new P-III trial is expected to be initiated in 2023. If tebipenem HBr is approved, it will be 1st oral carbapenem antimicrobial to receive marketing approval in the US
Ref: Globenewswire | Image: GSK
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at [email protected].